All
FDA Grants Keytruda, Cancer Vaccine Combo Breakthrough Therapy Designation for Melanoma
February 23rd 2023The designation is based on study findings demonstrating that the cancer vaccine-Keytruda combination reduces the risk of recurrence or death by 44% in the adjuvant setting for patients with melanoma.